白蛋白结合型紫杉醇治疗晚期原发性肝癌的效果观察

姬时宇; 胡毅

doi:10.3969/j.issn.1001-5256.2016.10.017

白蛋白结合型紫杉醇治疗晚期原发性肝癌的效果观察

DOI: 10.3969/j.issn.1001-5256.2016.10.017

姬时宇,
胡毅

解放军总医院肿瘤内一科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2538
- HTML全文浏览量: 32
- PDF下载量: 427
- 被引次数: 0
出版历程
- 收稿日期: 2016-05-23
- 出版日期: 2016-10-20

Clinical effect of albumin-bound paclitaxel in treatment of advanced primary liver cancer

Ji ShiYu,
Hu Yi

Department of Medical Oncology,Chinese PLA General Hospital

摘要

摘要:
目的探讨白蛋白结合型紫杉醇（Nab-P）一线治疗晚期原发性肝癌的临床效果和安全性。方法回顾分析2014年5月-2015年12月解放军总医院肿瘤内一科收治的23例晚期原发性肝癌患者的临床资料。按治疗方案分为观察组与对照组,观察组12例患者接受Nab-P治疗（其中Nab-P联合替吉奥5例,Nab-P联合卡培他滨5例,Nab-P单药2例）;对照组11例患者接受吉西他滨联合奥沙利铂治疗。各方案治疗21 d为1个周期,每治疗2个周期评价一次治疗效果,每个周期均评价不良反应。计数资料组间比较采用χ2检验或Fisher’s精确检验,采用Kaplan-Meier生存曲线评价无进展生存期,采用log-rank检验比较不同组别生存率。结果所有患者均可评价疗效和不良反应,观察组患者中部分缓解2例、疾病稳定7例、疾病进展3例;对照组患者中部分缓解2例、疾病稳定5例、疾病进展4例,2组疾病控制率比较,差异无统计学意义（75%vs 64%,χ2=0.350,P>0.05）。2组中位无进展生存时间比较差异亦无统计学意义[5.1（2.76.7）个月vs 4.3（2.55
- 肝肿瘤 /
- 白蛋白类 /
- 药物疗法,联合
Abstract:
Objective To investigate the clinical effect and safety of albumin-bound paclitaxel( Nab-P) as the first-line treatment for advanced primary liver cancer. Methods A retrospective analysis was performed for the clinical data of 23 patients with advanced primary liver cancer who were admitted to the Department of Medical Oncology in Chinese PLA General Hospital from May 2014 to December 2015.According to the treatment regimen,these patients were divided into observation group and control group. The 12 patients in the observation group were treated with Nab-P,among whom 5 were treated with Nab-P combined with tegafur,gimeracil and oteracil,5 were treated with Nab-P combined with capecitabine,and 2 were treated with Nab-P alone; the 11 patients in the control group were treated with gemcitabine combined with oxaliplatin. One cycle of the treatment was 21 days for each treatment regimen; therapeutic effect was evaluated every2 cycles,and adverse events were evaluated every cycle. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups,the Kaplan-Meier survival curves were used to analyze progression-free survival,and the log-rank test was used to compare survival rates between groups. Results All the patients were eligible for evaluation of clinical outcome and adverse events.In the observation group,2 patients achieved partial remission,7 had a stable disease,and 3 had a progressive disease; in the control group,2 achieved partial remission,5 had a stable disease,and 4 had a progressive disease. There was no significant difference in disease control rate between the two groups( 75% vs 64%,χ2= 0. 350,P > 0. 05). There was also no significant difference in the median progression-free survival between the two groups [5. 1( 2. 7-6. 7) months vs 4. 3( 2. 5-5. 4) months,χ2= 0. 647,P > 0. 05]. As for adverse events,no patient experienced serious adverse events,and there were significant differences in the incidence rates of platelet toxicity and increased aspartate aminotransferase between the two groups( χ2= 5. 490 and 6. 135,P = 0. 036 and 0. 027). Conclusion In the treatment of advanced primary liver cancer,the medication based on Nab-P shows a good clinical effect and tolerable toxic and side effects; however,due to the small sample size in this study,the clinical studies with a large sample size are needed.
- liver neoplasms /
- albumins /
- drug therapy

HTML全文

参考文献(21)

[1]CHEN WQ,ZHENG RS,BAADE PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.

[2]ROH Y,DAVID KC,SONG S,et al.The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation[J].Clin Transplant,2014,28(1):141-148.

[3]BRUIX J,SHERMAN M,LLOVET JM,et al.EASL panel of experts on HCC clinical management of hepatocellular carcinoma:conclusions of the Barcelona-2000 EASL conference[J].J Hepatol,2001,35(3):421-430.

[4]YE SL,CHEN RX.Comments on management of hepatocellular carcinoma:an update[J].Chin J Hepatol,2011,19(4):251-254.(in Chinese)叶胜龙,陈荣新.《肝细胞癌临床指南更新》解读[J].中华肝脏病杂志,2011,19(4):251-254.

[5]GONG S,SUN JM,TIAN LL,et al.Research progress of the anti-tumor effect of alkaloids of natural medicine[J].Jilin J Tradit Chin Med,2014,34(9):927-931.(in Chinese)宫爽,刘佳明,田淋淋,等.天然药物中生物碱类成分抗肿瘤活性[J].吉林中医药,2014,34(9):927-931.

[6]XIE LL,YANG TJ,ZHANG CP,et al.Clinical progress on nanoparticle albumin-bound paclitaxel[J].J Pharm Res,2014,33(5):289-291.

[7]LI Z,ZHANG WG,HAN XW.Recent advances in interventional therapy of hepatocellular carcinoma[J].World Chin J Dig,2011,19(3):221-226.(in Chinese)李臻,张文广,韩新巍.原发性肝细胞癌介入治疗的现状与进展[J].世界华人消化杂志,2011,19(3):221-226.

[8]RAOUL JL,SANGRO B,FOMER A,et al.Evolving strategies for the management of intermediate-stage hepatocellular carcinoma:available evidence and expert opinion on the use of transarterial chemoembo Iization[J].Cancer Treat Rev,2011,37(3):212-220.

[9]WANG F,QIN SK,HUA HQ,et al.Report of two cases of hepatitis B virus reactivation in primary liver carcinoma patients treated with the FOLFOX chemotherapy regimen[J].Chin J Hepatol,2014,22(3):236-238.(in Chinese)王锋,秦叔逵,华海清,等.FOLFOX4方案治疗晚期肝癌引起乙型肝炎病毒再激活2例报道[J].中华肝脏病杂志,2014,22(3):236-238.

[10]YI WL,FANG L,LIAO XL,et al.A clinical study of gemcitabine plus oxaliplatin in the treatment of advanced primary liver cancer[J].J Guangxi Med Univ,2014,31(5):756-760.(in Chinese)义维丽,房亮,廖小莉,等.吉西他滨联合奥沙利铂治疗中晚期原发性肝癌的临床疗效和安全性观察[J].广西医科大学学报,2014,31(5):756-760.

[11]LI HT,LEI YQ,HUANG JH,et al.Study of the efficacy and safety of GEMOX regimen for the patients with advanced primary liver cancer[J].J Clin Exp Med,2014,13(4):274-276.(in Chinese)李海涛,雷叶青,黄劲华,等.吉西他滨联合奥沙利铂治疗晚期原发性肝癌患者的疗效和安全性研究[J].临床和实验医学杂志,2014,13(4):274-276.

[12]ZHANG SM,ZHANG N.Research progress of hepatocellular carcinoma chemotherapy[J].Chin J New Drugs Clin Rem,2015,34(2):93-98.

[13]SWET JH,PACHECO HJ,IANNITI DA,et al.A silica-calcium-phosphate nanocomposite drug delivery system for the treatmentof hepatocellular carcinoma:in vivo study[J].J Biomed Mater Res,2014,102(1):190-202.

[14]WANG L,LI M,ZHANG N.Folate-targeted docetaxel-lipidbased-nanosuspensions for active-targeted cancer therapy[J].Int J Nanomed,2012,7(7):3281-3294.

[15]ZHOU Q,SUN X,ZENG L,et al.A randomized multicenter phaseⅡclinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma[J].Nanomedicine,2009,5(4):419-423.

[16]JOHN TA,VOGEL SM,TIRUPPATHI C,et al.Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer[J].Am J Physiol Lung Cell Mol Physiol,2003,184(1):184-196.

[17]TENERIELLO MG,TSENG PC,CROZIER M,et al.PhaseⅡevaluation of nanopartiele albumin-bound paclitaxel in platinumsensitive patients with recurrent ovarian,peritoneal,or fallopian tube cancer[J].J Clin Oncol,2009,27(9):1426-1431.

[18] 医療用医薬品:アブラキサン[EB/OL].http://www.kegg.jp/medicus-bin/japic_med?japic_code=00058810

[19]XU J,LIU ZS,ZHANG ZL.Effects of paclitaxel on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice[J].Wuhan Univ J Med Sci,2005,26(4):449-451.(in Chinese)许俊,刘志苏,张中林.紫杉醇对裸鼠人肝癌血管生成和肿瘤生长、转移的作用[J].武汉大学学报:医学版,2005,26(4):449-451.

[20]MA YL,QI HY,CAO ZD,et al.Studies on the preparation of docetaxel nano-liposomes and its treatment on liver cancer cells in vivo and in vitro[J].Chin J Biological Pharms,2015,35(6):43-47.(in Chinese)马友龙,祁海艳,曹振东,等.多西紫杉醇纳米脂质体的制备及其对肝癌细胞的体内外治疗研究[J].中国生化药物杂志,2015,35(6):43-47.

[21]ZHANG T,DUAN RC,ZHANG R.A retrospective analysis of combination of gemcitabine and docetaxel in patients with advanced hepatocellular carcinoma[J].Cancer Res Prevent Treat,2102,39(11):1369-1372.(in Chinese)张彤,段仁慈,张蕊.吉西他滨联合多西紫杉醇方案治疗晚期肝癌的临床观察[J].肿瘤防治研究,2102,39(11):1369-1372.

施引文献

资源附件(0)

访问统计